Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31951182)

  • 1. The Potential Targets and Mechanisms of a Carbazole and Pyrazole Containing Anticancer Compound.
    Xie J; Gore JC
    Curr Cancer Drug Targets; 2020; 20(5):364-371. PubMed ID: 31951182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
    Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer effects of KI-10F: a novel compound affecting apoptosis, angiogenesis and cell growth in colon cancer.
    Hong SW; Jung KH; Choi MJ; Kim DY; Lee HS; Zheng HM; Li GY; El-Deeb IM; Park BS; Lee SH; Hong SS
    Int J Oncol; 2012 Nov; 41(5):1715-22. PubMed ID: 22941304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.
    Shingu T; Holmes L; Henry V; Wang Q; Latha K; Gururaj AE; Gibson LA; Doucette T; Lang FF; Rao G; Yuan L; Sulman EP; Farrell NP; Priebe W; Hess KR; Wang YA; Hu J; Bögler O
    J Transl Med; 2016 Feb; 14():46. PubMed ID: 26861698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth.
    Ponnurangam S; Standing D; Rangarajan P; Subramaniam D
    Mol Cancer Ther; 2013 May; 12(5):598-609. PubMed ID: 23427297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier.
    Albanese C; Alzani R; Amboldi N; Degrassi A; Festuccia C; Fiorentini F; Gravina G; Mercurio C; Pastori W; Brasca M; Pesenti E; Galvani A; Ciomei M
    Br J Pharmacol; 2013 May; 169(1):156-66. PubMed ID: 23347136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of novel
    Chen H; Qiao C; Miao TT; Li AL; Wang WY; Gu W
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):1544-1561. PubMed ID: 31448648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis.
    D'Andrea MR; Mei JM; Tuman RW; Galemmo RA; Johnson DL
    Mol Cancer Ther; 2005 Aug; 4(8):1198-204. PubMed ID: 16093435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
    Wang W; Xu B; Li Q; Jiang D; Yan S
    Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, in vitro Antiproliferative and Antiinflammatory Activities, and Kinase Inhibitory effects of New 1,3,4-triarylpyrazole Derivatives.
    El-Gamal MI; Abdel-Maksoud MS; Gamal El-Din MM; Shin JS; Lee KT; Yoo KH; Oh CH
    Anticancer Agents Med Chem; 2017; 17(1):75-84. PubMed ID: 27334850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis of pyrazolo[3,4-d]pyrimidin-4(5H)-ones tethered to 1,2,3-triazoles and their evaluation as potential anticancer agents.
    Allam M; Bhavani AKD; Mudiraj A; Ranjan N; Thippana M; Babu PP
    Eur J Med Chem; 2018 Aug; 156():43-52. PubMed ID: 30006173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, in vitro anticancer activity and in silico studies of certain pyrazole-based derivatives as potential inhibitors of cyclin dependent kinases (CDKs).
    Mohammed EZ; Mahmoud WR; George RF; Hassan GS; Omar FA; Georgey HH
    Bioorg Chem; 2021 Nov; 116():105347. PubMed ID: 34555628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of novel pyrazole-based small molecular inhibitors of the STAT3 pathway in patient derived high grade glioma cells.
    Zhang L; Peterson TE; Lu VM; Parney IF; Daniels DJ
    PLoS One; 2019; 14(7):e0220569. PubMed ID: 31361777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.
    Zhang J; Zhou J; Ren X; Diao Y; Li H; Jiang H; Ding K; Pei D
    Invest New Drugs; 2012 Apr; 30(2):490-507. PubMed ID: 21080210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib mesylate inhibits proliferation of human colonic stromal fibroblasts in vitro and in vivo.
    Wang ZH; Li Q; Ruan SQ; Xiao Q; Liu Y; Hu YT; Hu LF; Chen HY; Zheng S; Zhang SZ; Ding KF
    J Zhejiang Univ Sci B; 2014 Aug; 15(8):701-12. PubMed ID: 25091988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity.
    Cheng C; Yun F; Ullah S; Yuan Q
    Eur J Med Chem; 2020 Mar; 189():112073. PubMed ID: 31991336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.
    Porchia LM; Guerra M; Wang YC; Zhang Y; Espinosa AV; Shinohara M; Kulp SK; Kirschner LS; Saji M; Chen CS; Ringel MD
    Mol Pharmacol; 2007 Nov; 72(5):1124-31. PubMed ID: 17673571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel small molecular inhibitors disrupt the JAK/STAT3 and FAK signaling pathways and exhibit a potent antitumor activity in glioma cells.
    Swiatek-Machado K; Mieczkowski J; Ellert-Miklaszewska A; Swierk P; Fokt I; Szymanski S; Skora S; Szeja W; Grynkiewicz G; Lesyng B; Priebe W; Kaminska B
    Cancer Biol Ther; 2012 Jun; 13(8):657-70. PubMed ID: 22555804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethyl 2-(benzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate analogues as a new scaffold for protein kinase casein kinase 2 inhibitor.
    Jin CH; Jun KY; Lee E; Kim S; Kwon Y; Kim K; Na Y
    Bioorg Med Chem; 2014 Sep; 22(17):4553-65. PubMed ID: 25131958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.